Metformin May Boost Lifespan for Older Women, Study Suggests

A long-term, observational study of 438 postmenopausal women with type 2 diabetes found that those who started metformin had about a 30% lower risk of dying before age 90 compared with those starting a sulfonylurea. The researchers caution that the design cannot prove causation, with no placebo group and limited generalizability to men or younger people, but the roughly 14–15 years of follow-up adds evidence to metformin’s potential anti-aging effects and the geroscience hypothesis, warranting randomized trials.